Publications by authors named "Darrin D Stuart"

Claim this Profile
S
STX-721, a Covalent EGFR/HER2 Exon 20 Inhibitor, Utilizes Exon 20-Mutant Dynamic Protein States and Achieves Unique Mutant Selectivity Across Human Cancer Models.
Raymond A Pagliarini, Jack A Henderson, Benjamin C Milgram, Deanna R Borrelli, Natasja Brooijmans, Darrin D Stuart

Clin Cancer Res· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of STX-721, a Covalent, Potent, and Highly Mutant-Selective EGFR/HER2 Exon20 Insertion Inhibitor for the Treatment of Non-Small Cell Lung Cancer.
Benjamin C Milgram, Deanna R Borrelli, Natasja Brooijmans, Jack A Henderson, Brendan J Hilbert, Darrin D Stuart

J Med Chem· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
STX-478, a Mutant-Selective, Allosteric PI3Kα Inhibitor Spares Metabolic Dysfunction and Improves Therapeutic Response in PI3Kα-Mutant Xenografts.
Leonard Buckbinder, David J St Jean, Trang Tieu, Brendon Ladd, Brendan Hilbert, Darrin D Stuart

Cancer Discov· November 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Precision Oncology Comes of Age: Designing Best-in-Class Small Molecules by Integrating Two Decades of Advances in Chemistry, Target Biology, and Data Science.
Darrin D Stuart, Angel Guzman-Perez, Natasja Brooijmans, Erica L Jackson, Gregory V Kryukov

Cancer Discov· October 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
RAF-Mutant Melanomas Differentially Depend on ERK2 Over ERK1 to Support Aberrant MAPK Pathway Activation and Cell Proliferation.
Matthew S Crowe, Tatiana Zavorotinskaya, Charles F Voliva, Matthew D Shirley, Yanqun Wang, Darrin D Stuart

Mol Cancer Res· June 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
LXH254, a Potent and Selective ARAF-Sparing Inhibitor of BRAF and CRAF for the Treatment of MAPK-Driven Tumors.
Kelli-Ann Monaco, Scott Delach, Jing Yuan, Yuji Mishina, Paul Fordjour, Darrin D Stuart

Clin Cancer Res· April 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Design and Discovery of -(3-(2-(2-Hydroxyethoxy)-6-morpholinopyridin-4-yl)-4-methylphenyl)-2-(trifluoromethyl)isonicotinamide, a Selective, Efficacious, and Well-Tolerated RAF Inhibitor Targeting RAS Mutant Cancers: The Path to the Clinic.
Savithri Ramurthy, Benjamin R Taft, Robert J Aversa, Paul A Barsanti, Matthew T Burger, Darrin D Stuart

J Med Chem· March 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Tumor Intrinsic Efficacy by SHP2 and RTK Inhibitors in KRAS-Mutant Cancers.
Huai-Xiang Hao, Hongyun Wang, Chen Liu, Steven Kovats, Roberto Velazquez, Darrin D Stuart

Mol Cancer Ther· December 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Distinct Transcriptional Programming Drive Response to MAPK Inhibition in -Mutant Melanoma Patient-Derived Xenografts.
Tianshu Feng, Javad Golji, Ailing Li, Xiamei Zhang, David A Ruddy, Darrin D Stuart

Mol Cancer Ther· December 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Hyperactivation of MAPK Signaling Is Deleterious to RAS/RAF-mutant Melanoma.
Grace P Leung, Tianshu Feng, Frederic D Sigoillot, Felipe C Geyer, Matthew D Shirley, Darrin D Stuart

Mol Cancer Res· January 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Antitumor Properties of RAF709, a Highly Selective and Potent Inhibitor of RAF Kinase Dimers, in Tumors Driven by Mutant RAS or BRAF.
Wenlin Shao, Yuji M Mishina, Yun Feng, Giordano Caponigro, Vesselina G Cooke, Darrin D Stuart

Cancer Res· March 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase I Dose-Escalation and -Expansion Study of the BRAF Inhibitor Encorafenib (LGX818) in Metastatic -Mutant Melanoma.
Jean-Pierre Delord, Caroline Robert, Marta Nyakas, Grant A McArthur, Ragini Kudchakar, Darrin D Stuart

Clin Cancer Res· September 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Design and Discovery of N-(2-Methyl-5'-morpholino-6'-((tetrahydro-2H-pyran-4-yl)oxy)-[3,3'-bipyridin]-5-yl)-3-(trifluoromethyl)benzamide (RAF709): A Potent, Selective, and Efficacious RAF Inhibitor Targeting RAS Mutant Cancers.
Gisele A Nishiguchi, Alice Rico, Huw Tanner, Robert J Aversa, Benjamin R Taft, Darrin D Stuart

J Med Chem· June 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of a Selective and Potent Inhibitor of Mitogen-Activated Protein Kinase-Interacting Kinases 1 and 2 (MNK1/2) Utilizing Structure-Based Drug Design.
Wooseok Han, Yu Ding, Yongjin Xu, Keith Pfister, Shejin Zhu, Darrin D Stuart

J Med Chem· April 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Molecular pathways: response and resistance to BRAF and MEK inhibitors in BRAF(V600E) tumors.
Meghna Das Thakur, Darrin D Stuart

Clin Cancer Res· March 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Molecular imaging of drug transit through the blood-brain barrier with MALDI mass spectrometry imaging.
Xiaohui Liu, Jennifer L Ide, Isaiah Norton, Mark A Marchionni, Maritza C Ebling, Darrin D Stuart

Sci Rep· October 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The evolution of melanoma resistance reveals therapeutic opportunities.
Meghna Das Thakur, Darrin D Stuart

Cancer Res· October 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Targeting RAF-MEK-ERK kinase-scaffold interactions in cancer.
Darrin D Stuart, William R Sellers

Nat Med· May 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
RAF inhibitors activate the MAPK pathway by relieving inhibitory autophosphorylation.
Matthew Holderfield, Hanne Merritt, John Chan, Marco Wallroth, Laura Tandeske, Darrin D Stuart

Cancer Cell· May 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Modelling vemurafenib resistance in melanoma reveals a strategy to forestall drug resistance.
Meghna Das Thakur, Fernando Salangsang, Allison S Landman, William R Sellers, Nancy K Pryer, Darrin D Stuart

Nature· February 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
RAF265 inhibits the growth of advanced human melanoma tumors.
Yingjun Su, Anna E Vilgelm, Mark C Kelley, Oriana E Hawkins, Yan Liu, Darrin D Stuart

Clin Cancer Res· April 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Inhibition of tumorigenesis driven by different Wnt proteins requires blockade of distinct ligand-binding regions by LRP6 antibodies.
Seth A Ettenberg, Olga Charlat, Michael P Daley, Shanming Liu, Karen J Vincent, Darrin D Stuart

Proc Natl Acad Sci U S A· August 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
High efficiency entrapment of antisense oligonucleotides in liposomes.
Darrin D Stuart, Sean C Semple, Theresa M Allen

Methods Enzymol· July 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis